Journal article
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes
Abstract
OBJECTIVE: Glycemic variability may contribute to adverse medical outcomes of type 2 diabetes, but prior therapies have had limited success in controlling glycemic fluctuations, and the hypothesis has not been adequately tested.
RESEARCH DESIGN AND METHODS: People with insulin-requiring type 2 diabetes and high cardiovascular risk were enrolled during a run-in period on basal-bolus insulin (BBI), and 102 were randomized to continued BBI or to …
Authors
Probstfield JL; Hirsch I; O'Brien K; Davis B; Bergenstal R; Kingry C; Khakpour D; Pressel S; Branch KR; Riddle M
Journal
Diabetes Care, Vol. 38, No. 8, pp. 1558–1566
Publisher
American Diabetes Association
Publication Date
August 1, 2015
DOI
10.2337/dc14-2689
ISSN
0149-5992
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AlbuminuriaBiomarkersBlood GlucoseBody WeightDiabetes Mellitus, Type 2Diabetic AngiopathiesExenatideFemaleGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansHypoglycemic AgentsInsulinInsulin GlargineInsulin, Long-ActingMaleMetforminMiddle AgedPeptidesPostprandial PeriodRisk FactorsTime FactorsVenoms